WaveMan
WaveMan · Company
LYEL · Lyell Immunopharma, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

LYEL Lyell Immunopharma (LYEL) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001806952
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
51
13F, latest reported quarter

What the filings say about LYEL

Insiders, 180 days
-$255.5K net sold
7 sellers · 0% of sales under a 10b5-1 plan

Lyell Immunopharma insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Lyell Immunopharma, Inc. insiders sold a net $255.5K of stock across 50 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Aguirre Jarrad Mattieu
Chief Medical Officer
SELL
2026-10-13 SECtraded 2026-10-12
422
$3.6K
+16.5%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 2.1% of the 19,857 shares held after it.
  • No other insider sold within 30 days.
  • 51 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Aguirre Jarrad Mattieu sold about $3.6K of LYEL on Oct 12, 2026; 51 funds added in the latest 13F quarter.
Shook David
Chief Medical Officer
SELL
2026-09-10 SEC
500
$6.3K
-22.2%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jun 10, 2026.
  • The trade is 2.4% of the 20,423 shares held after it.
  • 3 other insiders sold within 30 days.
  • 51 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Shook David sold about $6.3K of LYEL on Sep 10, 2026; 3 other insiders sold within 30 days and 51 funds added in the latest 13F quarter.
Lee Gary K.
Chief Scientific Officer
SELL
2026-08-25 SECtraded 2026-08-21
1,457
$22.6K
-37.1%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Aug 10, 2026.
  • The trade is 9.0% of the 16,220 shares held after it.
  • 4 other insiders sold within 30 days.
  • 51 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Lee Gary K. sold about $22.6K of LYEL on Aug 21, 2026; 4 other insiders sold within 30 days and 51 funds added in the latest 13F quarter.
Hill Stephen J.
Chief Operating Officer
SELL
2026-08-25 SECtraded 2026-08-21
989
$15.4K
-37.1%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Aug 10, 2026.
  • The trade is 5.9% of the 16,816 shares held after it.
  • 4 other insiders sold within 30 days.
  • 51 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Hill Stephen J. sold about $15.4K of LYEL on Aug 21, 2026; 4 other insiders sold within 30 days and 51 funds added in the latest 13F quarter.
Seely Lynn
President and CEO
SELL
2026-08-25 SECtraded 2026-08-21
9,589
$149.0K
-37.1%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (1 buy, 8 sales), the last on Aug 10, 2026.
  • The trade is 15.0% of the 63,899 shares held after it.
  • 4 other insiders sold within 30 days.
  • 51 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Seely Lynn sold about $149.0K of LYEL on Aug 21, 2026; 4 other insiders sold within 30 days and 51 funds added in the latest 13F quarter.
50 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 45 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$255.5K over 180 days
-$214.7K over 90 days · -$274 of it by a 10%+ holder
more than 50% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
51 funds bought in last quarter
below 52% of Pharma & Biotech
Revenue
-41.0% year over year
below 77% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
10.4% of the float short (float per yahoo 2026-10-26) · 7.4 days to cover · settled 2026-09-30
more than 51% of Pharma & Biotech
What changed in the last 30 days
Oct 13Chief Medical Officer Aguirre Jarrad Mattieu sold $3.6K (Oct 12)

Watch LYEL

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-49.2%12M
-59%-2%+54%+111%2025-102025-122026-022026-042026-062026-082026-10 2026-03-06 · ARCH Venture Partners IX Overage, L.P. bought $12.5M2026-03-06 · BERNS PAUL L bought $12.5M2026-02-11 · Seely Lynn sold $174.4K2026-08-21 · Seely Lynn sold $149.0K2025-12-24 · Bulis Veronica Sanchez sold $43.9K2026-02-11 · Lee Gary K. sold $39.1K2025-12-30 · Bulis Veronica Sanchez sold $30.3K2026-02-11 · Hill Stephen J. sold $28.9K2026-06-10 · Shook David sold $25.0K2026-08-21 · Lee Gary K. sold $22.6K2026-08-21 · Hill Stephen J. sold $15.4K2026-02-10 · Seely Lynn sold $10.1K2026-08-10 · Bulis Veronica Sanchez sold $8.9K2026-05-11 · Seely Lynn sold $7.3K2025-11-10 · Seely Lynn sold $6.6K2026-09-10 · Shook David sold $6.3K2026-02-10 · Bulis Veronica Sanchez sold $5.9K2026-08-10 · Seely Lynn sold $5.6K2026-05-11 · Bulis Veronica Sanchez sold $4.1K2025-11-10 · Bulis Veronica Sanchez sold $3.8K2026-10-12 · Aguirre Jarrad Mattieu sold $3.6K2026-02-10 · Lee Gary K. sold $3.4K2026-02-10 · Hill Stephen J. sold $2.5K2026-05-11 · Lee Gary K. sold $2.5K2025-11-10 · Lee Gary K. sold $2.2K2026-08-10 · Lee Gary K. sold $1.9K2026-05-11 · Hill Stephen J. sold $1.7K2025-11-10 · Hill Stephen J. sold $1.5K2026-08-10 · Hill Stephen J. sold $1.3K2026-07-16 · Innovative Cellular Therapeutics Holdings Ltd sold $1372026-07-17 · Innovative Cellular Therapeutics Holdings Ltd sold $137
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns LYEL: institutional holders (13F)

13F holdings, latest reported quarter
ARCH Venture Management, LLC
3,247,162 sh
$45.5M
GSK plc
1,512,659 sh
$21.3M
VANGUARD CAPITAL MANAGEMENT LLC
786,774 sh
$11.1M
Orland Properties Ltd
754,698 sh
$10.6M
BlackRock, Inc.
724,342 sh
$10.2M

Congress trades in LYEL

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

LYEL planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

LYEL mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$252.9K position · as of 2026-06-30
0.2%
Allspring Disciplined Small Cap Fund
$151.9K position · as of 2026-06-30
0.1%
Small Cap Value Fund
$398.3K position · as of 2026-06-30
0.1%
iShares Micro-Cap ETF
$443.7K position · as of 2026-06-30
0.0%
Invesco Nasdaq Biotechnology ETF
$19.4K position · as of 2026-05-31
0.0%
ProShares Ultra Nasdaq Biotechnology
$13.6K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
7 registered trials, 3 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 1
0 active
1
Phase 3
1 active
1
Not applicable
0 active
3
Multi-phase
2 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $255.5K sold by insiders over 180 days, 51 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

LYEL financials

Revenue growth
-41.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$27.0K
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
-$134.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-93.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-71.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-82.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-58.7%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$36.0K$61.0K$130.0K$84.7M
Operating income-$269.4M-$358.8M-$247.0M-$187.1M
Net income-$274.4M-$343.0M-$234.6M-$183.1M
EPS (diluted)-16.06-26.23-18.70-0.74
Operating cash flow-$150.0M-$162.4M-$163.7M-$169.6M
Cash$60.2M$105.6M$145.6M$123.6M
Buybacksn/an/an/a$0
SEC XBRL, fiscal years, as known on 2026-10-28

LYEL Stock Sonar score 5/7 axes

Find similar shapesCompare

LYEL ranks highest on institutional and government (48th percentile) and risk and compliance (35th), and lowest on growth (23rd), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
33
Inputs
  • Return on equity-93.3% · 35 pct, sector of 545
  • Return on assets-71.3% · 33 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-82.8% · 32 pct, sector of 576
Growth
23
Inputs
  • Revenue growth, YoY-41.0% · 23 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
24
Inputs
  • Net Form 4 buying (codes P and S), 180d-$256K · 48 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
48
Inputs
  • Funds adding, latest quarter51 · 48 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
35
Inputs
  • Short interest, % of float+10.4% · 38 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+14.1% · 33 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

LYEL filings, in plain words

Are Lyell Immunopharma insiders buying or selling LYEL?

In the 180 days to 2026-10-28, Lyell Immunopharma insiders were net sellers, a net $255.5K across purchases and sales reported on Form 4, by 7 sellers.

Read the full summary

In the 180 days to 2026-10-28, Lyell Immunopharma insiders were net sellers of LYEL, a net $255.5K across purchases and sales reported on Form 4 by 7 sellers. None of the 16 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies